Oncostar
Russia
Siberian Federal District of the Russian Federation
Central Federal District of the Russian Federation
Moscow
Bolshoi bldg., p.42, p.1, 143026
Oncostar is engaged in the development and promotion of anti-tumor drugs based on recombinant strains of oncolytic viruses.
History
2022: Attracting 64 million rubles for testing a drug against breast cancer
Oncostar, a resident of, Skolkovo conducted preliminary tests medicine for breast cancer human therapy and attracted 64 million from rubles private investors. The funds will allow the completion of the first phase of clinical trials by mid-2023. The product is developed on the basis of a genetically modified oncolytic, virus officially authorized for clinical trials. The Skolkovo Foundation announced this on December 14, 2022. More. here
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |